From the Food and Drug Administration.
Nightingale
S L
SL
Office of Health Affairs, FDA, Rockville, MD 20857, USA.
D002292:Carcinoma, Renal Cell / Q000188:drug therapy; D017277:Drug Approval; D015507:Drugs, Investigational; D005910:Glioma / Q000188:drug therapy; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D006801:Humans; D007255:Information Services; D007546:Isoquinolines / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000188:drug therapy; D011643:Publishing / Q000592:standards*; D011804:Quinolines / Q000627:therapeutic use*; D019258:Saquinavir; D014481:United States; D014486:United States Food and Drug Administration
D015507:Drugs, Investigational; D017320:HIV Protease Inhibitors; D007546:Isoquinolines; D011804:Quinolines; D019258:Saquinavir